Replies to post #561 on Emerging World Pharma, Inc. (EWPI)

[mahi mahi man]

Here is an e-mail I rcvd from Brandon Keks on 9/2/2011. It obviousely hasn't came to fruition..??


I understand your concern regarding your investment in EWPI. Please remain
patient and hold on to your investment as you should see a rebound by the
end of the year and increase through 2012.
African Global Pharma (GH) Ltd's plant is located in Sunyani, Ghana.
Pre-approval has already been granted for our building, equipment, staff,
packaging and environmental policy. The initial product line for AGP is
pending full approval for sale by the Ghana Food and Drug Board. Samples
and dossiers have been submitted and we anticipate full approval of our
anti-malarial products by November 2011.

The plant address is:

African Global Pharma (GH) Ltd.
Diocesan Bldg.
Plot 7/19-A
Sunyani Industrial
Sunyani BA
Ghana

If you would like to speak with AGP's Managing Director his name is Mr.
Roy Duodu Sarpong. You can reach him at 1-647-926-1677.


Sincerely,

Brandon Keks

[The_Medik]

They are current with their financials, Sept 2012 and they are putting out news:

Emerging World Pharma Inc. President Provides Update From Global Pharma Corp. Annual Meeting

SUNYANI, GHANA, Oct 26, 2012 (MARKETWIRE via COMTEX) -- Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- Emerging World Pharma president Steve Ignatavicius was in attendance at the annual meeting of the board of directors from the company's strategic partner African Global Pharma Corp. The primary focus of the meeting was the restructuring and consolidation of operations at African Global Pharma Corp. GH.
The board of directors ratified the appointment of African Global Pharma GH president ROY ANTHONY DUODU-SARPONG. Mr. Roy Duodu-Sarpong will oversee all operations in the company's facility in Ghana. Mr. Duodo-Sarpong is a Business Executive with management skills in the Information Technology and Financial Institutions business sector. He previously worked in consulting and management positions at US West Communications through AIC, Ontario Hydro, Bank of Montreal, Royal Bank of Canada and Nortel Networks. Roy is a professional who believes that industries and people must be receptive to change when the world turns. He possesses a natural ability for negotiation and gentle persuasion, making him a perfect candidate to deal with contracts and manage a turn-key project. He holds an MBA Degree from the Centre of Graduate Management School at Keele.

The directors also agreed to put on hiatus the project in Estonia until final review. Moving forward, African Global Pharma Corp. intends to introduce a line of over-the-counter pharmaceuticals it will be making available beginning November 1, 2012.

About African Global Pharma, Ghana African Global Pharma (Ghana) Limited is an affiliated company of African Global Pharma Corp. of Canada with business partnership with the Catholic Diocese of Sunyani to distribute all our manufactured drugs to the Catholic Mission Hospitals. African Global Pharma's production facility in Sunyani, Ghana was fully rehabilitated and built by African Global Pharma Corp, Canada. The plant and its operations are headquartered in Sunyani at the Diocesan Bldg.

For more on AGP, click here http://www.globalpharmacorp.ca/african-gp-ghana.html

About Emerging World Pharma Inc. Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

For more on Emerging World Pharma Inc., click here http://www.emergingpharma.com/

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact:
Joel Everret
Emerging World Pharma Inc.
Investor Relations Division
703-646-2633
Email: [e-mail]
Website: http://www.emergingpharma.com/


SOURCE: Emerging World Pharma Inc.
CONTACT: mailto:[e-mail]
http://www.emergingpharma.com/

Copyright 2012 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Trials